Loading market dashboard
GBS Inc.
GBSHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
Filing date: May 20, 2026GAAP diluted EPS was $11.09, which is higher than the estimated EPS of $10.65.Revenue was $8,558 million, which is below the estimated
Hansa Biopharma enters into â¬115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA PR New
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl.
Transaction Overview On March 20, 2026, Larry Robbins (Trades, Portfolio), through Glenview Capital Management, increased the firm's stake in DXC Technology Co
